The New England Journal of Medicine reported an important finding in 2019 from a Yale-led clinical trial: for the first time, researchers showed that a drug, teplizumab, could delay the development of type 1 diabetes by two years.
Kevan Herold, MD, C.N.H. Long Professor of Immunology and professor of medicine (endocrinology), and the principal investigator of the trial, said teplizumab likely will be FDA-approved in mid-November for people who are at high risk of diabetes, not only those with a family history of the disease. Once approved, all children should be screened for diabetes risk so that those at high risk will have a chance to prevent or at least delay the disease, Herold said.
Any delay in the onset of a chronic disease is valuable, Herold said. If youre eight years old, and you delay diabetes by two years or longer, thats a long time, he said. Kids become more mature. Theyre better able manage the disease.
The teplizumab trial is just one example of how Yale School of Medicine is a leader in the study and treatment of diabetes. At the Yale Diabetes Research Center, founded in 1993, researchers work to better understand type 1 and type 2 diabetes. At the Yale Diabetes Center, founded in 1994, physicians translate that knowledge into patient treatments.
An estimated 34.2 million people in the U.S., or 10.5% of the population, have diabetes. Characterized by abnormally high blood sugar levels, diabetes occurs when the body cannot make or becomes resistant to insulin, which the bodys cells need to take in and store blood sugar, called glucose. To manage their blood sugar, people with diabetes must take insulin and watch what they eat. Complications of type 1 and type 2 diabetes can include cardiovascular disease, as well as eye, foot, and kidney problems.
Preventing type 1 diabetes
The Yale Diabetes Research Center, funded by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), is one of 16 NIDDK-funded diabetes research hubs nationwide. Researchers investigate type 1 and type 2 diabetes in children and adults and gestational diabetes. They also study the immunobiology of diabetes, cell and vascular biology, and obesity. The center is the site of 23 NIH-funded diabetes clinical trials.
In people with type 1 diabetes, the body mounts an autoimmune attack against the pancreas cells that produce insulin. Teplizumab is an antibody that counteracts that response and will be the first drug that prevents an autoimmune disease. Were very excited about that, said Herold, co-director of the Yale Diabetes Research Center.
In Herolds trial, 76 participants who were at high risk for type 1 diabetes and had diabetic relatives, were randomly assigned to take teplizumab or a placebo for two weeks. They took periodic glucose tolerance tests until they developed diabetes, or the trial ended. By the trials end, 57% of participants who received teplizumab were diabetes free, compared with 28% of those who received the placebo.
The results of the trial represent a paradigm shift for autoimmune research, Herold said. If diabetes can be prevented, perhaps other autoimmune diseases, such as rheumatoid arthritis or multiple sclerosis, can be, too. Herold is hopeful that researchers can begin to shift the way we think about these widespread diseases and find people who are going to develop them and stop the disease before it actually happens.
Insulin Resistance in type 2 Diabetes
Gerald I. Shulman, MD, PhD, MACP, MACE, George R. Cowgill Professor of Medicine (endocrinology) and professor of cellular and molecular physiology, and co-director of the Yale Diabetes Research Center, has spent the past 30 years investigating what causes insulin resistance and type 2 diabetes.
Shulman and colleagues began investigating these findings using nuclear magnetic resonance spectroscopy (NMR), combined with stable isotopes as a noninvasive way to trace metabolic flux in an organ-specific fashion in humans and transgenic rodents. They found insulin resistance in muscle could be attributed to reduced insulin-stimulated glucose transport and that people with insulin resistance have fat stored in places in their body, such as the liver and muscle, where fat is normally not stored.
Its really not how much fat a person has that drives insulin resistance, its where the fat is stored, Shulman explained. When fat is stored ectopically, in liver and skeletal muscle, thats what drives insulin resistance and leads to the development of metabolic syndrome, cardiovascular disease, and type 2 diabetes. The most striking example are patients with lipodystrophy. They have virtually no fat but are profoundly insulin-resistant due to fat accumulation in their liver and muscle cells. When we treat them with leptin, the fat in these organs disappears and their insulin resistance and diabetes resolves.
As reported in a 2007 paper in the journal PNAS, a study led by Kitt Petersen, MD, professor of medicine (endocrinology), found that in lean people with insulin resistance -- but who did not yet have diabetes -- the liver accumulated unusually large amounts of fat. The study also found that fat built up in the blood of insulin-resistant subjects, setting the stage for cardiovascular disease. In 2022, Petersen published a paper in JCI Insight that showed that even lower liver fat content than previously believed is associated with insulin resistance and increased cardiometabolic risks.
However, the researchers also have found that diet and exercise can combat both ectopic fat storage and insulin resistance. A 2011 PNAS article from Shulmans group found that in lean, insulin-resistant but non-diabetic people, 45 minutes of leg exercise led skeletal muscle to respond to insulin again and decreased liver fat storage after a meal. In a 2005 study led by Petersen and published in the journal Diabetes, obese, diabetic patients who lost about 10% of their body weight saw their diabetes and insulin resistance go away and their liver fat return to normal levels.
Shulmans group has elucidated the molecular basis for lipid-induced insulin resistance in liver, skeletal muscle, and white adipose tissues, which has led to several new drugs for NAFLD/NASH and type 2 diabetes. One of these new drugs rids the liver of its excess fat. The drug, a controlled-release mitochondrial protonophore (CRMP), revs up the mitochondria in the liver, causing them to burn more fat. Studies have shown that CRMP can totally reverse these conditions, and CRMP is undergoing IND enabling studies.
Improving Diabetes Treatments
The increased risk of cardiovascular problems for diabetes patients remains even when patients control their blood sugar, said Silvio Inzucchi, MD, professor of medicine (endocrinology) and medical director of the Yale Diabetes Center.
Even though it's intuitive to think that good control of diabetes could mitigate those complications, that actually does not end up to be so, Inzucchi said. It's been a little bit of a conundrum as to why, if you fix the major underlying problem with diabetes, can't you decrease the rates of these complications. This has been one of my interest areas for many years.
Two relatively new classes of type 2 diabetes drugs can mitigate cardiovascular symptoms while helping control blood sugar. In 2015, Inzucchi and colleagues reported in the New England Journal of Medicine that type 2 diabetes patients randomly assigned to the type 2 diabetes drug empagliflozin had a lower risk of dying from cardiovascular causes than those assigned to the placebo. Empagliflozin, which the FDA approved in 2014, is an SGLT2 inhibitor. SGLT2 inhibitors reduce blood sugar by causing the kidneys to release more glucose into the urine. The drug also decreases the risk of kidney problems, Inzucchi said.
A different class of type 2 diabetes drug, the GLP-1 receptor agonists, has also been associated with reductions in cardiovascular complications as well as significant weight loss, Inzucchi said. GLP-1 receptor agonists stimulate the body to produce more insulin but also do several other things like reducing appetite, leading to weight loss. William Tamborlane, MD, professor of pediatrics (endocrinology), led the study, published in the New England Journal of Medicine in 2019, leading to the pediatric indication of one such GLP-1 receptor agonist, liraglutide, for youth with type 2 diabetes.
Between those two drug classes, we now have solid evidence that these medications can not only lower the glucose to help with diabetes control, but also prevent heart complications of diabetes, Inzucchi said. With these multi-functional drugs, clinicians at the Yale Diabetes Center can tailor diabetes treatment regimens to patients needs, Inzucchi added. Thats been a real sea change in our field.
Additionally, a novel GIP/GLP-1 receptor agonist, tirzepatide, was recently shown to be extremely effective for weight loss. People with obesity treated with tirzepatide lost about 52 pounds on average, according to results of a study that were published in the New England Journal of Medicine. Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology) and pediatrics (pediatric endocrinology), was the lead author of the study.
Advances in Technology
Diabetes used to be a disease of daily shots: fingersticks to check blood sugar, then injections of insulin. But according to Inzucchi, the toolkit he and his colleagues have for helping type 1 and type 2 diabetes patients has expanded in recent years.
For type 1 diabetes, I think the major advancement has been the technology, Inzucchi said. In 2016, for example, the FDA approved a device that measures patients blood sugar levels every five minutes through a continuous glucose monitor and sends the information to a pump that delivers insulin accordingly. The system, called a hybrid closed loop insulin delivery system because the person with diabetes still needs to take a bolus of insulin before a meal, is connected to patients 24/7 and allows for more physiologic insulin delivery, Inzucchi said. Stuart Weinzimer, MD, professor (pediatric endocrinology and diabetes) and the interim chief of pediatric endocrinology, led the Yale site of the trial that led to this devices approval. Tamborlane, chief of pediatric endocrinology for over 37 years, guided pioneering studies in the development of insulin pump therapy, continuous glucose monitors, and automated insulin delivery systems. Weinzimer also has conducted longitudinal studies characterizing the effects of diabetes on brain development in youth with type 1 diabetes.
Pediatric Partners
Jennifer Sherr, MD, PhD, professor in pediatrics (endocrinology), Michelle Van Name, MD, assistant professor of pediatrics (endocrinology), and Laura Marie Nally, MD, assistant professor of pediatrics and of pediatric endocrinology and diabetes, are national leaders in helping youth with type 1 diabetes to manage this chronic medical condition. They have conducted continued work on new automated insulin delivery systems and new treatments for type 1 diabetes. Sonia Caprio, MD, professor of pediatrics (endocrinology), has studied obesity and type 2 diabetes for 25 years, and her work has brought the magnitude of the childhood obesity problem to national attention. Stephanie Samuels, MD, instructor of pediatrics has also focused her work on the care of youth with type 2 diabetes.
Continue reading here:
Diabetes Treatment and Research at Yale: 30 Years of Progress - Yale School of Medicine
- Proof-of-Concept Exploit Released for Progress Software OpenEdge Vulnerability - The Hacker News - March 16th, 2024 [March 16th, 2024]
- Progress being made on fire alarms, Oswego town supervisor says - oswegocountynewsnow.com - March 16th, 2024 [March 16th, 2024]
- Progress on the Boyertown Express featured at Dinner - Berks Weekly - March 16th, 2024 [March 16th, 2024]
- Fire Crews Stop Forward Progress of Two-Acre Brush Fire Near Vandenberg - Santa Barbara Edhat - March 16th, 2024 [March 16th, 2024]
- Hopewell plans to install speed cameras at three city schools - Progress Index - March 16th, 2024 [March 16th, 2024]
- New numbers on progress of penny sales tax - The Post and Courier - March 16th, 2024 [March 16th, 2024]
- Long Island woman who survived acid attack continues to make progress in recovery - PIX11 New York News - March 16th, 2024 [March 16th, 2024]
- Beam marks progress toward bringing 1st-ever MLS team to San Diego - NBC San Diego - March 16th, 2024 [March 16th, 2024]
- McKone: Irish-American progress and paradoxes | Perspective | timesargus.com - Barre Montpelier Times Argus - March 16th, 2024 [March 16th, 2024]
- Big East reportedly making a lot of progress on media rights deals with CBS, Fox - Awful Announcing - March 16th, 2024 [March 16th, 2024]
- Berrien County farmers note slow progress on the new Farm Bill - News/Talk/Sports 94.9 WSJM - March 16th, 2024 [March 16th, 2024]
- END OF SESSION: Sen. Crider and Rep. Cherry reflect on progress made during the legislative session - Greenfield Daily Reporter - March 16th, 2024 [March 16th, 2024]
- Vowles being patient with Sargeant but expects to see "progress" - RaceFans - March 16th, 2024 [March 16th, 2024]
- Inflation ticked up in February, reversing some prior progress - ABC News - March 16th, 2024 [March 16th, 2024]
- Latest NEOM progress video of The Line is indicator of scale - Supercar Blondie - March 16th, 2024 [March 16th, 2024]
- Statewide Impact of Ohio Intel ProjectEvident in Initial Progress Report - Scioto Post - March 16th, 2024 [March 16th, 2024]
- SpaceX makes significant progress with third Starship orbital test flight - TechCrunch - March 16th, 2024 [March 16th, 2024]
- UPDATE: Forward progress stopped on vegetation fire near Lompoc - KSBY News - March 16th, 2024 [March 16th, 2024]
- Lady Rattlers and Diamondbacks ready to roll - Progresstimes - March 16th, 2024 [March 16th, 2024]
- SpaceX celebrates major progress on the third flight of Starship - Ars Technica - March 16th, 2024 [March 16th, 2024]
- Helldivers 2 Galactic War live map: Track status and progress with this Liberty-approved web app - Windows Central - March 16th, 2024 [March 16th, 2024]
- Pittsburgh police will only respond to calls of in-progress emergencies as part of new staffing plan - Police News - March 16th, 2024 [March 16th, 2024]
- A year of achievement, rebuilding and progress for utilities - Yoursun.com - March 16th, 2024 [March 16th, 2024]
- Trkiye: No Direct Dialogue with Damascus, No Progress in Normalization - Asharq Al-awsat - English - March 16th, 2024 [March 16th, 2024]
- A WORK IN PROGRESS | News | shelbynews.com - Shelbynews - March 16th, 2024 [March 16th, 2024]
- From recurrent networks to GPT-4: Measuring algorithmic progress in language models - Tech Xplore - March 16th, 2024 [March 16th, 2024]
- U.S. Inability To Address Nuclear Waste Harms Environmental Progress - Newsweek - March 16th, 2024 [March 16th, 2024]
- Park Progress - Greater Wilmington Business Journal - March 16th, 2024 [March 16th, 2024]
- SF supervisor to hold hearing on homeless-shelter progress | Housing | sfexaminer.com - San Francisco Examiner - March 16th, 2024 [March 16th, 2024]
- 'It's good to see progress being made on the site': Revised vision for Liberty Theater property in Libertyville - Daily Herald - March 16th, 2024 [March 16th, 2024]
- Diversity Among Emmy Winners Is a Result of Industry Progress - TheWrap - January 18th, 2024 [January 18th, 2024]
- What would Dr. King say about progress and 2024? - The Chicago Cusader - January 18th, 2024 [January 18th, 2024]
- Police: Petersburg woman reportedly used hammer to hit her boyfriend - Progress Index - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - AOL - January 18th, 2024 [January 18th, 2024]
- Lady Tigers Split Last Weeks Game's Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Lexington Police Investigate Shooting at Walmart Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Scotts Hill Lions Dominated Last Week Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Older Couple Rescued From Submerged Vehicle Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Fore-ward Progress | Bintelli's new River Ridge facility to focus on making electric golf carts - WDRB - January 18th, 2024 [January 18th, 2024]
- VIDEO: Project manager gives update on Glenn McConnell Widening progress - Live 5 News WCSC - January 18th, 2024 [January 18th, 2024]
- Truck driver sentenced for trafficking cocaine to Prince George County - Progress Index - January 18th, 2024 [January 18th, 2024]
- After decades of little progress, Milwaukee begins new approach to improve lives of Black men and boys - madison365.com - January 18th, 2024 [January 18th, 2024]
- Women are bored of waiting: Slow progress on shattering the glass ceiling on company boards - I by IMD - I by IMD - January 18th, 2024 [January 18th, 2024]
- Now Accepting Applications for the 2024 Progress Software Mary Szkely Scholarship for Women in STEM - GlobeNewswire - January 18th, 2024 [January 18th, 2024]
- "Some progress made" at Onslow BOE meeting, according to number of parents - WCTI12.com - January 18th, 2024 [January 18th, 2024]
- Spokane County crews make great progress ahead of another storm system - Nonstop Local - January 18th, 2024 [January 18th, 2024]
- DeSantis took credit for Florida's progress but Iowa may have sniffed out his bravado | Opinion - Yahoo News Canada - January 18th, 2024 [January 18th, 2024]
- Has the Israeli Military Made Progress in Its Goal of Destroying Hamas? : State of the World from NPR - NPR - January 18th, 2024 [January 18th, 2024]
- Jan. 19 Panel Examines 30-Year Progress of Women in Research - Mirage News - January 18th, 2024 [January 18th, 2024]
- Ducks' Midseason Check-in: Progress, Improvement Areas & More - The Hockey Writers - January 18th, 2024 [January 18th, 2024]
- Companies are hiding their climate progress. A new report explains why. - Grist - January 18th, 2024 [January 18th, 2024]
- Lou Leonatti With Progress Mexico Gives Hospital Bankruptcy Hearing Update On AM 1340 KXEO Am I Awake Morning Show - KXEO - January 18th, 2024 [January 18th, 2024]
- Seaside Heights Wants to See Progress From Developers, Will Investigate 'Bamboo' Property - Shorebeat - January 18th, 2024 [January 18th, 2024]
- Progress over perfection: Is Coach modelling a path for fashion transformation? - Vogue Business - January 18th, 2024 [January 18th, 2024]
- Watch the video of the Edmonds armed robbery in progress - MyNorthwest - January 18th, 2024 [January 18th, 2024]
- Albemarle County house burns to the ground in late night fire - The Daily Progress - January 18th, 2024 [January 18th, 2024]
- GHDDI and Microsoft Research use AI technology to achieve significant progress in discovering new drugs to treat ... - Microsoft - January 18th, 2024 [January 18th, 2024]
- Henderson County Suspects Apprehended in Trenton Lexington Progress - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- HCFD Reports Lowest Number of Residential Fires - lexingtonprogress.com - January 18th, 2024 [January 18th, 2024]
- Unlocking The Future: CAGA's Progress In Web3 And Blockchain Innovation - Benzinga - January 18th, 2024 [January 18th, 2024]
- Underwhelming performance: Quarterbacks still a work in progress - Daily O'Collegian - September 3rd, 2023 [September 3rd, 2023]
- Governor Hochul Announces Progress in Increasing MTA Accessibility - ny.gov - September 3rd, 2023 [September 3rd, 2023]
- A progress report: The columnist's garden in September - Kennebec Journal and Morning Sentinel - September 3rd, 2023 [September 3rd, 2023]
- September 2023: Innovative researchers celebrate scientific ... - Environmental Factor Newsletter - September 3rd, 2023 [September 3rd, 2023]
- Progress over perfectionism - Lynn University - September 3rd, 2023 [September 3rd, 2023]
- Signs of progress on new Folsom Medical Office Building - UC Davis Health - September 3rd, 2023 [September 3rd, 2023]
- LA District FUDS team makes progress on Nellis Remedial Action ... - spl.usace.army.mil - September 3rd, 2023 [September 3rd, 2023]
- UFC Fight Night 226 winner Volkan Oezdemir pleased with progress after training with Khamzat Chimaev - Yahoo Sports - September 3rd, 2023 [September 3rd, 2023]
- Seeing signs of progress, Tigers take on White Sox - Deadspin - September 3rd, 2023 [September 3rd, 2023]
- Qualifications recognition: A door to collective progress - University World News - September 3rd, 2023 [September 3rd, 2023]
- Farm Progress Show opens on Tuesday in Decatur - Herald & Review - September 3rd, 2023 [September 3rd, 2023]
- General Squier sculpture is in progress - The County Press - Thecountypress - September 3rd, 2023 [September 3rd, 2023]
- Antimalarial drug discovery: progress and approaches - Nature.com - September 3rd, 2023 [September 3rd, 2023]
- Seeing signs of progress, Tigers take on White Sox - The Albany Herald - September 3rd, 2023 [September 3rd, 2023]
- Commentary: Nurturing progress The evolution of the Annie ... - Standard-Examiner - September 3rd, 2023 [September 3rd, 2023]
- World Cup kiss: feminist progress is always met with backlash, but ... - The Conversation - September 3rd, 2023 [September 3rd, 2023]
- Mapping Progress in Pancreatic Cancer Surgery: Looking to the ... - OncLive - September 1st, 2023 [September 1st, 2023]
- Review in progress: 'Starfield' takes the 'Skyrim' formula out into the ... - GeekWire - September 1st, 2023 [September 1st, 2023]
- Falmouth Water Quality Committee Making Progress On Ocean Outfall - CapeNews.net - September 1st, 2023 [September 1st, 2023]
- Youngstown schools, teachers make progress on negotiations ... - Youngstown Vindicator - September 1st, 2023 [September 1st, 2023]